111, Inc. (YI) 股票分析

公司概述

111, Inc. operates as an integrated online and offline platform within the healthcare market of the People's Republic of China, delivering supply chain integration services to assist pharmaceutical companies in managing their product distribution. The company functions through two distinct segments, B2C and B2B, which collectively define its operational scope in medical distribution. As of the latest data, the entity holds a market capitalization of $56.16M and employs a workforce of 1238 individuals, while generating annual revenue of $13.58B. These financial dimensions suggest that despite its significant revenue generation, the company operates with a relatively modest market valuation, indicating a potential disconnect between its sales scale and investor pricing or suggesting that the market is discounting its earnings due to current profitability challenges.

财务健康

The company reported a trailing twelve-month revenue of $13.58B alongside a net income loss of $-70,012,000, creating a substantial gap that reveals a highly cost-structured business where operating expenses and losses significantly erode top-line growth. In terms of cash generation, the free cash flow stands at $-22,583,250, indicating that the company is currently burning cash and lacks the immediate internal liquidity to fund operations without external financing. Profitability metrics across the board show compression, with a gross margin of 2.8%, an operating margin of -0.1%, and a profit margin of -0.5%, highlighting the difficulty in converting sales into actual profit within this low-margin distribution model. Regarding the balance sheet, the company holds $493.62M in cash against $204.73M in debt, yet the debt-to-equity ratio remains elevated at 93.56, suggesting a leveraged financial position despite the cash buffer. Short-term liquidity is maintained at a current ratio of 1.07, which indicates that current assets barely cover current liabilities, leaving little room for error in working capital management. Furthermore, the return on equity is -10.9% and the return on assets is -0.2%, metrics that collectively reveal that management has not been effective in generating positive returns on the capital invested or utilized by the firm in the recent period.

估值评估

Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at 46.29, implying that the market is pricing in significant future earnings recovery or restructuring that has not yet materialized in historical data. The price-to-book ratio is recorded at -0.57, a negative figure that indicates the market values the company below its book value, often seen in distressed or turnaround situations where assets are not being monetized efficiently. Alternative valuation multiples such as the price-to-sales ratio of 0.00 and an EV/EBITDA of 437.63 further underscore the extreme difficulty in valuing the stock using traditional multiples, as the negative earnings render these ratios either zero or exceptionally high. The stock's trading range over the past year spans from a 52-week low of $2.48 to a high of $11.17, meaning the current share price sits at a specific point within this volatile band, reflecting high uncertainty. The beta value of 0.70 suggests that the stock price exhibits lower volatility relative to the broader market, moving roughly 30% less than the market index, which might offer some downside protection but also limits upside potential during market rallies.

Growth & Income

Revenue growth year-over-year has declined by 16.7%, while earnings growth is listed as N/A, indicating that earnings are not growing at all and are instead contracting, which implies a deterioration in the fundamental business model rather than a temporary lag in reporting. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, choosing instead to reinvest its limited earnings or utilize cash reserves to fund operations and potentially reduce debt rather than returning capital to shareholders. The overall growth and income profile is characterized by negative revenue expansion and an absence of dividend income, reflecting a mature or struggling phase in the medical distribution sector where capital preservation is prioritized over expansion or shareholder payouts. This combination of declining sales and zero dividend distribution paints a picture of a company currently focused on survival and operational restructuring rather than capital appreciation or income generation.